Teleflex

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teleflex reports Q4 growth amidst challenges, eyes revenue acceleration

Teleflex's Q4 performance showed resilience with revenue growth and strategic acquisitions. While facing challenges like supply chain disruptions and UroLift revenue decline, the company is focused on margin expansion and disciplined growth. Opportunities lie in revenue acceleration, international expansion, and leveraging high-growth product categories.

Teleflex reports robust Q1 earnings, eyes growth amid challenges

Teleflex's Q1 2023 results reflect strong performance and strategic focus on sustainable growth, supported by geographic revenue growth and product category contributions.
While facing challenges in specific product lines and supply chain issues, the company maintains a disciplined approach to deals and cost management.
Opportunities lie in revised revenue guidance, product performance, and market improvements, positioning Teleflex for continued success in 2023.

Teleflex reports revenue growth and strategic acquisitions drive future outlook

Teleflex revised its 2023 financial guidance with revenue growth of 5.5% to 6.25% and adjusted EPS of $13 to $13.60. Despite challenges in certain product segments, the company remains confident in achieving its Long Range Plan growth objectives. The focus on integrating acquisitions like Palette and leveraging high-growth products positions Teleflex for continued success.

Teleflex reports robust Q3 results, eyes growth amidst challenges

Teleflex's Q3 performance reflects revenue and EPS growth, driven by operational improvements.
Despite challenges from GLP-1 impact and tax rate increases, the company remains optimistic.
Opportunities lie in market expansion, M&A activities, and product uniqueness strategies.
Overall, Teleflex's strong financials and strategic initiatives position it for continued growth.

Teleflex reports solid 2023 performance, eyes growth in Urology market

Teleflex's 2023 performance showed revenue growth and strong cash flow, with guidance for 2024 indicating continued growth and margin targets.
Despite challenges like declining EPS and recall impacts, the company aims for high EPS growth and sees opportunities in new markets and product expansions.
Confidence in meeting targets, pursuing strategic initiatives, and navigating market challenges position Teleflex for growth and profitability in the coming years.
Balancing financial performance with strategic investments and operational improvements will be key for Teleflex to capitalize on growth opportunities and overcome challenges.

Teleflex reports solid Q1 performance, eyes growth through acquisitions

Teleflex's Q1 2024 performance was solid, with revenue growth, margin expansion, and strong cash flow. Despite challenges like market multiples and recall impacts, the company is focused on growth opportunities and disciplined acquisitions to drive future success.

Teleflex reports solid Q2 growth, eyes M&A and product innovation

Teleflex's Q2 performance reflects steady growth, driven by strong results in key segments and product categories.
Despite challenges in certain areas, the company's strategic initiatives, including acquisitions and product innovation, position it well for future success.
With a focus on revenue growth, operational efficiency, and shareholder value, Teleflex is poised to capitalize on opportunities and navigate challenges effectively.

Teleflex reports solid Q3 earnings, eyes growth amid challenges

Teleflex's Q3 2024 performance showcased revenue growth, margin improvement, and strategic acquisitions driving increased revenue guidance for the year.
While facing challenges in specific product categories, the company's focus on innovation, market expansion, and financial strength positions it well for future growth.
Opportunities in expanding markets, disciplined capital allocation, and strong cash flow generation underscore Teleflex's resilience and potential for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teleflex, Inc. provides medical technology products which enable healthcare providers to improve patient outcomes and enhance patient and provider safety. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.

Teleflex (TFX) Q3 Earnings Top Estimates, Adjusted EPS View Cut

Teleflex, Inc. (NYSE:TFX ) Q3 2022 Earnings Conference Call October 27, 2022 8:00 AM ET Company Participants Lawrence Keusch - Vice President of Investor Relations & Strategy Development Liam Kelly - Chairman, President & Chief Executive Officer Thomas Powell - Executive Vice President & Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Jayson Bedford - Raymond James Shagun Singh - RBC Matt Taylor - Jefferies Mike Polark - Wolfe Research Craig Bijou - Bank of America Merrill Lynch Anthony Petrone - Mizuho Richard Newitter - Truist Michael Matson - Needham & Company Operator Good morning, ladies and gentlemen and welcome to the Teleflex Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and will be available on the company's website for replay shortly.

Teleflex, Inc. (TFX) Q3 2022 Earnings Call Transcript

WAYNE, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 25, 2022.

Teleflex Reports Third Quarter Financial Results And Full Year Outlook

Men with obstructive median lobes treated with the UroLift ® System experience symptom improvement sooner and are satisfied more quickly compared to those treated with TURP, and have fewer post-op catheterizations

Published Data Demonstrate Consistent PUL Outcomes for the Treatment of Median Lobe Obstruction Across Controlled and Real-World Settings

Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

WAYNE, Pa., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 27, 2022.

Teleflex Announces Third Quarter 2022 Earnings Conference Call Information

Differentiated Stapling Technology for Bariatric Surgery Differentiated Stapling Technology for Bariatric Surgery

Teleflex Completes Acquisition of Standard Bariatrics

Midline options designed to fit the needs of clinicians and patients Midline options designed to fit the needs of clinicians and patients

Teleflex launches new Arrow® Pressure Injectable Midline Catheter Portfolio

Teleflex's (TFX) lowered revenue and adjusted EPS outlook for 2022 indicates lackluster performance, which increases investors' concern.

Teleflex (TFX) Witnesses Lower UroLift Sales, Cost Woes

Results from Largest Ever Real-World Evaluation of the MANTA® Device Demonstrated Safety and Effectiveness with Low Complication Rates and a Short Learning Curve Results from Largest Ever Real-World Evaluation of the MANTA® Device Demonstrated Safety and Effectiveness with Low Complication Rates and a Short Learning Curve

Co-Author of the Karolinska 1000 Consecutive MANTA® Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

WAYNE, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York, on Wednesday, September 14, 2022 at 10:00 a.m. (ET).

Teleflex to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

FundamentalVR Offers Teleflex a Scalable Training Platform to Accelerate the Effective Use of the UroLift® 2 System for Treatment of Enlarged Prostate

Teleflex Announces Collaboration with FundamentalVR, to Improve Training Through Virtual Reality Simulation

Signs Definitive Agreement to Acquire Standard Bariatrics Signs Definitive Agreement to Acquire Standard Bariatrics

Teleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery

In the Americas, growth within the Surgical business of Teleflex (TFX) is offset by a decline in Interventional Urology.

Teleflex (TFX) Hit by Urolift Volume Decline, Cost Pressure

For UroLift, Teleflex (TFX) witnesses revenue declines in all sites of service, including hospital, ASC and physician's office.

Teleflex's (TFX) Q2 Earnings Top Estimates, 2022 View Down

WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has been awarded a contract for the supply of Central Venous Access products from Vizient, Inc., the nation's largest member-driven healthcare performance improvement company. The agreement is effective starting August 1, 2022.

Teleflex awarded Central Venous Access contract from Vizient

Highlights path forward for Corporate Social Responsibility program Highlights path forward for Corporate Social Responsibility program

Teleflex Publishes 2021 Global Impact Report

Teleflex, Inc. (NYSE:TFX ) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Lawrence Keusch - VP, IR & Strategy Development Liam Kelly - Chairman, President & CEO Thomas Powell - EVP & CFO Conference Call Participants Cecilia Furlong - Morgan Stanley Jayson Bedford - Raymond James & Associates Shagun Chadha - RBC Capital Markets Michael Polark - Wolfe Research Richard Newitter - Truist Securities Michael Matson - Needham & Company Matthew Mishan - KeyBanc Capital Markets Craig Bijou - Bank of America Merrill Lynch Matthew O'Brien - Piper Sandler & Co. Operator Good morning, ladies and gentlemen. Welcome to the Teleflex Second Quarter 2022 Earnings Conference Call.

Teleflex, Inc. (TFX) CEO Liam Kelly on Q2 2022 Results - Earnings Call Transcript

Teleflex (TFX) delivered earnings and revenue surprises of 1.19% and 2.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Q2 Earnings Beat Estimates

WAYNE, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 26, 2022.

Teleflex Reports Second Quarter Financial Results And Full Year Outlook

WAYNE, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 28, 2022.

Teleflex Announces Second Quarter 2022 Earnings Conference Call Information

Presentations at the 37th Annual European Association of Urology Congress to Demonstrate Measurable and Sustained Improvement of BPH Symptoms and IPSS Scores Presentations at the 37th Annual European Association of Urology Congress to Demonstrate Measurable and Sustained Improvement of BPH Symptoms and IPSS Scores

New Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged Prostate

Study Intends to Demonstrate that Ultrasound Allows for Precise Deployment and Positive Positioning of the MANTA® Vascular Closure Device Study Intends to Demonstrate that Ultrasound Allows for Precise Deployment and Positive Positioning of the MANTA® Vascular Closure Device

Teleflex Announces First Patient Enrollment in MANTA Ultra Study

Designed to help clinicians overcome catheter identification confusion Designed to help clinicians overcome catheter identification confusion

News for Teleflex Stock (TFX)